GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001493152-26-023346
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$2.83M | -$776.00K | -$2.27M | -$227.00K |
| EPS Diluted | -$0.11 | -$0.33 | -$1.64 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
